S68 Phase 1 trial of an intranasal respiratory syncytial virus (rsv) subunit candidate vaccine: safety results from the muc-syngem study | Thorax

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

Asthma: infection and inflammation

S68 Phase 1 trial of an intranasal respiratory syncytial virus (rsv) subunit candidate vaccine: safety results from the muc-syngem study

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Vlachantoni I, Ascough S, Grimaldi R, et al

S68 Phase 1 trial of an intranasal respiratory syncytial virus (rsv) subunit candidate vaccine: safety results from the muc-syngem study

Thorax 2017;72:A43-A44.